Actinium Pharmaceuticals Stock Performance
| ATNM Stock | USD 1.44 0.03 2.13% |
The firm shows a Beta (market volatility) of 0.93, which signifies possible diversification benefits within a given portfolio. Actinium Pharmaceuticals returns are very sensitive to returns on the market. As the market goes up or down, Actinium Pharmaceuticals is expected to follow. At this point, Actinium Pharmaceuticals has a negative expected return of -0.32%. Please make sure to confirm Actinium Pharmaceuticals' treynor ratio, kurtosis, as well as the relationship between the Kurtosis and day typical price , to decide if Actinium Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Actinium Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in December 2024. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
Last Split Factor 1:30 | Dividend Date 2020-08-11 | Last Split Date 2020-08-11 |
1 | Actinium Pharmaceuticals Inc May Have Violated Securities Regulations And The Schall Law Firm Invites Investors To Help With An Investigation | 09/10/2024 |
2 | Actinium Pharmaceuticals, Inc. Is Being Investigated For Violating Securities Laws And Impacted Stockholders Are Urged To Contact The Schall Law Firm | 09/27/2024 |
3 | The Schall Law Firm Encourages Investor Participation In An Inquiry Into Actinium Pharmaceuticals Incs Possible Securities Fraud | 10/14/2024 |
4 | The Schall Law Firm Encourages Investors To Join An Inquiry Into Actinium Pharmaceuticals Inc For Securities Fraud | 10/18/2024 |
5 | The Schall Law Firm Encourages Investor Participation In An Inquiry Into Actinium Pharmaceuticals Inc For Securities Fraud | 10/22/2024 |
6 | Actinium Pharmaceuticals, Inc. Is Being Investigated For Violations Of Securities Laws And Affected Shareholders Should Contact The Schall Law Firm | 10/30/2024 |
7 | Insider Trading | 11/01/2024 |
8 | Telix and Eckert Ziegler to Partner on Actinium-225 Production Technology | 11/13/2024 |
9 | Actinium Pharmaceuticals Inc Quarterly 10-Q Report - Quartz | 11/14/2024 |
10 | Actinium Pharmaceuticals Highlights Antibody Radiation Conjugate Program Developments and Reports Financial Results for the Third Quarter 2024 | 11/18/2024 |
11 | NorthStar Medical Radioisotopes Executes Supply Agreement With Cellectar Biosciences for Therapeutic Radioisotope Actinium-225 | 11/21/2024 |
| Begin Period Cash Flow | 109.6 M |
Actinium |
Actinium Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 187.00 in Actinium Pharmaceuticals on September 1, 2024 and sell it today you would lose (43.00) from holding Actinium Pharmaceuticals or give up 22.99% of portfolio value over 90 days. Actinium Pharmaceuticals is currently does not generate positive expected returns and assumes 4.256% risk (volatility on return distribution) over the 90 days horizon. In different words, 37% of stocks are less volatile than Actinium, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Actinium Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Actinium Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Actinium Pharmaceuticals, and traders can use it to determine the average amount a Actinium Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0763
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ATNM |
Estimated Market Risk
| 4.26 actual daily | 37 63% of assets are more volatile |
Expected Return
| -0.32 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.08 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Actinium Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Actinium Pharmaceuticals by adding Actinium Pharmaceuticals to a well-diversified portfolio.
Actinium Pharmaceuticals Fundamentals Growth
Actinium Stock prices reflect investors' perceptions of the future prospects and financial health of Actinium Pharmaceuticals, and Actinium Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Actinium Stock performance.
| Return On Equity | -0.88 | ||||
| Return On Asset | -0.31 | ||||
| Operating Margin | (576.65) % | ||||
| Current Valuation | (32.03 M) | ||||
| Shares Outstanding | 31.2 M | ||||
| Price To Earning | (1.45) X | ||||
| Price To Book | 1.18 X | ||||
| Price To Sales | 554.59 X | ||||
| Revenue | 81 K | ||||
| Gross Profit | 1.03 M | ||||
| EBITDA | (51.13 M) | ||||
| Net Income | (48.82 M) | ||||
| Cash And Equivalents | 116.33 M | ||||
| Cash Per Share | 4.62 X | ||||
| Total Debt | 2.11 M | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 18.83 X | ||||
| Book Value Per Share | 1.32 X | ||||
| Cash Flow From Operations | (47.34 M) | ||||
| Earnings Per Share | (1.39) X | ||||
| Market Capitalization | 44.92 M | ||||
| Total Asset | 81.44 M | ||||
| Retained Earnings | (337.58 M) | ||||
| Working Capital | 69.77 M | ||||
| Current Asset | 26.48 M | ||||
| Current Liabilities | 4.61 M | ||||
About Actinium Pharmaceuticals Performance
By examining Actinium Pharmaceuticals' fundamental ratios, stakeholders can obtain critical insights into Actinium Pharmaceuticals' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Actinium Pharmaceuticals is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.60) | (0.57) | |
| Return On Capital Employed | (0.71) | (0.68) | |
| Return On Assets | (0.60) | (0.57) | |
| Return On Equity | (1.34) | (1.27) |
Things to note about Actinium Pharmaceuticals performance evaluation
Checking the ongoing alerts about Actinium Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Actinium Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Actinium Pharmaceuticals generated a negative expected return over the last 90 days | |
| Actinium Pharmaceuticals may become a speculative penny stock | |
| Actinium Pharmaceuticals has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 81 K. Net Loss for the year was (48.82 M) with profit before overhead, payroll, taxes, and interest of 1.03 M. | |
| Actinium Pharmaceuticals currently holds about 116.33 M in cash with (47.34 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.62, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from finance.yahoo.com: NorthStar Medical Radioisotopes Executes Supply Agreement With Cellectar Biosciences for Therapeutic Radioisotope Actinium-225 |
- Analyzing Actinium Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Actinium Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Actinium Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Actinium Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Actinium Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Actinium Pharmaceuticals' stock. These opinions can provide insight into Actinium Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Actinium Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Actinium Stock, please use our How to Invest in Actinium Pharmaceuticals guide.You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Actinium Pharmaceuticals. If investors know Actinium will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Actinium Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.39) | Revenue Per Share 0.003 | Quarterly Revenue Growth (1.00) | Return On Assets (0.31) | Return On Equity (0.88) |
The market value of Actinium Pharmaceuticals is measured differently than its book value, which is the value of Actinium that is recorded on the company's balance sheet. Investors also form their own opinion of Actinium Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Actinium Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Actinium Pharmaceuticals' market value can be influenced by many factors that don't directly affect Actinium Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Actinium Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Actinium Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Actinium Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.